Login Sign up free
Home Stock ScreenerScreener ETF ScreenerETF Maps Charts News Groups Insider Futures Forex Crypto Watchlist Portfolio Calendar
Pricing
Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Get 50% Off Elite

CBIO

Crescent Biopharma Inc

Last Close
14.76
Nov 11 • 3:59 PM ET Dollar change0.00 Percentage change(0.00%)
Overview Compare Short Interest Financials Options Filings Dilution
Healthcare Biotechnology USA Small NASD
Peers: SMMT BCAX BNTX MGNX ZYME STRO CTMX PYXS WHWK XLO
 | Held by: VTI IWM VXF XBI IWO VTWO IWC VHT VTWG RSSL
Scroll to Statements
Index
RUT
Market Cap
548.06M
Enterprise Value
381.91M
Income
-165.12M
Sales
11.88M
Book/sh
5.74
Cash/sh
4.62
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
44
IPO
Jan 10, 2014
P/E
-
Forward P/E
-
PEG
-
P/S
46.13
P/B
2.57
P/C
3.19
P/FCF
-
EV/EBITDA
-
EV/Sales
32.15
Quick Ratio
9.66
Current Ratio
9.66
Debt/Eq
0.01
LT Debt/Eq
0.01
Option/Short
Yes / Yes
EPS (ttm)
-7.65
EPS next Y
-3.19
EPS next Q
-0.70
EPS this Y
78.00%
EPS next Y
-13.31%
EPS next 5Y
37.23%
EPS past 3/5Y
45.01% 33.26%
Sales past 3/5Y
424.86% 1.31%
EPS Y/Y TTM
78.59%
Sales Y/Y TTM
-100.00%
EPS Q/Q
85.60%
Sales Q/Q
-
Earnings
Jul 30 BMO
EPS/Sales Surpr.
-0.58% -100.00%
Insider Own
16.78%
Insider Trans
14.07%
Inst Own
79.31%
Inst Trans
10.29%
ROA
-97.08%
ROE
-109.17%
ROIC
-100.55%
Gross Margin
98.22%
Oper. Margin
-1417.74%
Profit Margin
-1389.58%
SMA20
11.55%
SMA50
-1.71%
SMA200
-7.28%
Trades
Shs Outstand
37.14M
Shs Float
30.91M
Short Float
13.46%
Short Ratio
12.10
Short Interest
4.16M
52W High
27.41 -46.17%
52W Low
8.72 69.21%
Volatility
8.01% 7.72%
ATR (14)
1.07
RSI (14)
57.53
Beta
1.37
Rel Volume
0.00
Avg Volume
343.85K
Volume
0
Perf Week
6.77%
Perf Month
14.29%
Perf Quarter
-11.27%
Perf Half Y
-24.76%
Perf YTD
24.41%
Perf Year
11.36%
Perf 3Y
-87.70%
Perf 5Y
-92.73%
Perf 10Y
-97.78%
Recom
1.00
Target Price
31.50
Prev Close
14.76
Price
14.76
Change %
0.00%
Consensus
Strong Buy
Avg. Price Target
$31.50
Implied Upside
+113.5%
Analysts12incl. previous ratings
Rating Distribution9 Buy · 3 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 06, 2026Upgrade
HH.C. Wainwright
Neutral → Buy$36+144.0%
Jun 01, 2026Downgrade
HH.C. Wainwright
Buy → Neutral
Jan 28, 2026Initiated
PPiper Sandler
Overweight$35+137.2%
Jan 21, 2026Initiated
GGuggenheim
Buy$35+137.2%
Aug 25, 2025Initiated
JEF logoJJefferies
Buy$26+76.2%
Aug 11, 2025Initiated
HH.C. Wainwright
Buy$25+69.4%
Jul 14, 2025Initiated
WWedbush
Outperform$27+83.0%
Jun 25, 2025Initiated
SF logoSStifel
Buy$28+89.8%
Mar 21, 2025Initiated
CCantor Fitzgerald
Overweight
Jul 26, 2024Downgrade
TD logoTTD Cowen
Buy → Hold
Show Previous News
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lynch RyanSee RemarksSep 16 '26Sale17.902404,29613,631Sep 18 04:03 PM
Pinkas JanChief Scientific OfficerSep 16 '26Sale17.9065811,77821,581Sep 18 04:03 PM
Im Ellie EunkyungChief Medical OfficerSep 16 '26Sale17.9062311,15221,446Sep 18 04:02 PM
Scalzo Richard WilliamChief Financial OfficerSep 16 '26Sale17.9056810,16719,730Sep 18 04:02 PM
Bispham Barbara HarlinSee RemarksSep 16 '26Sale17.9062011,09818,710Sep 18 04:02 PM
Brumm Joshua TChief Executive OfficerSep 18 '26Sale16.717,837130,956271,765Sep 18 04:02 PM
Brumm Joshua TChief Executive OfficerSep 16 '26Sale17.901,61028,819279,602Sep 18 04:02 PM
McNeill JonathanPresident and COOSep 18 '26Sale16.713,83964,150134,588Sep 18 04:01 PM
McNeill JonathanPresident and COOSep 16 '26Sale17.9073113,085138,427Sep 18 04:01 PM
Joshua T BrummOfficerSep 18 '26Proposed Sale17.189,013154,843Sep 17 04:33 PM
Jonathan McNeillOfficerSep 18 '26Proposed Sale17.184,41575,850Sep 17 04:32 PM
Jonathan McNeillOfficerSep 16 '26Proposed Sale18.8080415,115Sep 16 03:09 PM
Joshua T BrummOfficerSep 16 '26Proposed Sale18.801,77133,295Sep 16 03:09 PM
Fairmount Funds Management LLCDirectorJul 16 '26Buy14.50853,45012,375,0253,601,316Jul 20 05:30 PM
Lynch RyanSee RemarksJun 22 '26Sale17.994658,36513,871Jun 23 04:04 PM
Pinkas JanChief Scientific OfficerJun 22 '26Sale17.991,28823,17122,239Jun 23 04:04 PM
Scalzo Richard WilliamChief Financial OfficerJun 22 '26Sale17.991,11220,00520,298Jun 23 04:03 PM
Bispham Barbara HarlinSee RemarksJun 22 '26Sale17.991,21821,91219,330Jun 23 04:03 PM
Im Ellie EunkyungChief Medical OfficerJun 22 '26Sale17.991,21921,93022,069Jun 23 04:02 PM
McNeill JonathanPresident and COOJun 22 '26Sale17.9920,549369,677139,158Jun 23 04:02 PM
Brumm Joshua TChief Executive OfficerJun 22 '26Sale17.9942,305761,067281,212Jun 23 04:01 PM
Fairmount Funds Management LLCDirectorDec 04 '25Buy13.411,360,00018,237,6002,747,866Dec 08 04:30 PM
Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.
CEO & DirectorMr. Joshua T. Brumm
President & COODr. Jonathan McNeill M.D.
Chief Medical OfficerDr. Ellie Im M.D.
Chief Financial OfficerMr. Richard William Scalzo M.B.A.
Senior VP of FinanceMr. Ryan Lynch
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)